In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...

THURSDAY, Sept. 12, 2024 (HealthDay News) -- It could be a real breakthrough for people at risk for HIV infection: A shot ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...

They have been able to harvest healthy stem cells - the building blocks of life - from a diseased pancreas and mature them into insulin-producing cells.

New research on the efficacy and safety of twice-yearly subcutaneous lenacapavir is summarized in a short video.

Lenacapavir, a twice-yearly injectable antiretroviral, reduced the risk of HIV infection by 96% in a large study of gay and bisexual men and gender diverse people, according to a Gilead Sciences ...

This week, young people are making disasters their own through memes, convincing their boyfriends to do interpretive dance, ...

we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP.” While the results are good news, the drug is expensive. The National Institutes of Health have ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...